Cargando…

Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment

Breast cancer (BC) currently occupies the second rank in cancer-related global female deaths. Although consistent awareness and improved diagnosis have reduced mortality in recent years, late diagnosis and resistant response still limit the therapeutic efficacy of chemotherapeutic drugs (CDs), leadi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rani, Ruma, Malik, Parth, Dhania, Sunena, Mukherjee, Tapan Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860911/
https://www.ncbi.nlm.nih.gov/pubmed/36678856
http://dx.doi.org/10.3390/pharmaceutics15010227
_version_ 1784874709145354240
author Rani, Ruma
Malik, Parth
Dhania, Sunena
Mukherjee, Tapan Kumar
author_facet Rani, Ruma
Malik, Parth
Dhania, Sunena
Mukherjee, Tapan Kumar
author_sort Rani, Ruma
collection PubMed
description Breast cancer (BC) currently occupies the second rank in cancer-related global female deaths. Although consistent awareness and improved diagnosis have reduced mortality in recent years, late diagnosis and resistant response still limit the therapeutic efficacy of chemotherapeutic drugs (CDs), leading to relapse with consequent invasion and metastasis. Treatment with CDs is indeed well-versed but it is badly curtailed with accompanying side effects and inadequacies of site-specific drug delivery. As a result, drug carriers ensuring stealth delivery and sustained drug release with improved pharmacokinetics and biodistribution are urgently needed. Core–shell mesoporous silica nanoparticles (MSNPs) have recently been a cornerstone in this context, attributed to their high surface area, low density, robust functionalization, high drug loading capacity, size–shape-controlled functioning, and homogeneous shell architecture, enabling stealth drug delivery. Recent interest in using MSNPs as drug delivery vehicles has been due to their functionalization and size–shape-driven versatilities. With such insights, this article focuses on the preparation methods and drug delivery mechanisms of MSNPs, before discussing their emerging utility in BC treatment. The information compiled herein could consolidate the database for using inorganic nanoparticles (NPs) as BC drug delivery vehicles in terms of design, application and resolving post-therapy complications.
format Online
Article
Text
id pubmed-9860911
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98609112023-01-22 Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment Rani, Ruma Malik, Parth Dhania, Sunena Mukherjee, Tapan Kumar Pharmaceutics Review Breast cancer (BC) currently occupies the second rank in cancer-related global female deaths. Although consistent awareness and improved diagnosis have reduced mortality in recent years, late diagnosis and resistant response still limit the therapeutic efficacy of chemotherapeutic drugs (CDs), leading to relapse with consequent invasion and metastasis. Treatment with CDs is indeed well-versed but it is badly curtailed with accompanying side effects and inadequacies of site-specific drug delivery. As a result, drug carriers ensuring stealth delivery and sustained drug release with improved pharmacokinetics and biodistribution are urgently needed. Core–shell mesoporous silica nanoparticles (MSNPs) have recently been a cornerstone in this context, attributed to their high surface area, low density, robust functionalization, high drug loading capacity, size–shape-controlled functioning, and homogeneous shell architecture, enabling stealth drug delivery. Recent interest in using MSNPs as drug delivery vehicles has been due to their functionalization and size–shape-driven versatilities. With such insights, this article focuses on the preparation methods and drug delivery mechanisms of MSNPs, before discussing their emerging utility in BC treatment. The information compiled herein could consolidate the database for using inorganic nanoparticles (NPs) as BC drug delivery vehicles in terms of design, application and resolving post-therapy complications. MDPI 2023-01-09 /pmc/articles/PMC9860911/ /pubmed/36678856 http://dx.doi.org/10.3390/pharmaceutics15010227 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rani, Ruma
Malik, Parth
Dhania, Sunena
Mukherjee, Tapan Kumar
Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment
title Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment
title_full Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment
title_fullStr Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment
title_full_unstemmed Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment
title_short Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment
title_sort recent advances in mesoporous silica nanoparticle-mediated drug delivery for breast cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860911/
https://www.ncbi.nlm.nih.gov/pubmed/36678856
http://dx.doi.org/10.3390/pharmaceutics15010227
work_keys_str_mv AT raniruma recentadvancesinmesoporoussilicananoparticlemediateddrugdeliveryforbreastcancertreatment
AT malikparth recentadvancesinmesoporoussilicananoparticlemediateddrugdeliveryforbreastcancertreatment
AT dhaniasunena recentadvancesinmesoporoussilicananoparticlemediateddrugdeliveryforbreastcancertreatment
AT mukherjeetapankumar recentadvancesinmesoporoussilicananoparticlemediateddrugdeliveryforbreastcancertreatment